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Measures to Reduce Diagnostic Error and Improve Clinical 
Decision Making in Thyroid FNA Aspiration Cytology:  
A Proposed Framework
David N. Poller, MD, FRCPath 1; Sarah J. Johnson, MBBS, PhD, FRCPath2;  
and Massimo Bongiovanni, MD 3
Thyroid fine-needle aspiration cytology (FNA) and histopathology can be subjective areas of medical diagnosis and sub-
ject to different interpretations. On the basis of the authors' personal experience, 12 recommendations with potential to 
improve clinical decision making, ensure quality, and reduce diagnostic error in thyroid FNAC and histopathology are pre-
sented. 1) use a standardized reporting terminology for thyroid FNAC; 2) understand and explain to service users the limi-
tations of cytology and the standardized thyroid FNAC reporting terminology used; 3) the cytopathologist should review 
all relevant clinical and ultrasound findings, if feasible; 4) include the risk of malignancy in all FNAC reports if feasible; 5) 
collect data to calculate the local institutional risk of malignancy for FNAC if feasible; 6) accept that nondiagnostic FNAC 
will include small numbers of carcinomas; 7) use rapid on-site evaluation and/or educational sessions for aspirators if the 
nondiagnostic aspiration rate is high; 8) know the diagnostic pitfalls of both cytology and histopathology; 9) use special 
immunohistochemical and molecular techniques that are evidence-based; 10) make use of second opinions, either in-house 
or interinstitutional; 11) multidisciplinary discussion of cases before surgery or therapy is invaluable; and, finally, 12) manage 
patient and clinician expectations of thyroid cytology and histopathology. These 12 recommendations may assist in quality-
improvement initiatives and may reduce diagnostic errors in thyroid cytology and histopathology. Thyroid multidisciplinary 
case discussion remains the principal, overarching method for error reduction and for providing high-quality clinical decision 
making. Cancer Cytopathol 2020;0:1-11. © 2020 The Authors. Cancer Cytopathology published by Wiley Periodicals LLC 
on behalf of American Cancer Society This is an open access article under the terms of the Creative Commons Attribution-
NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly 
cited, the use is non-commercial and no modifications or adaptations are made. 
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INTRODUCTION
Medical diagnostic error is defined in a report from the US Institute of Medicine as failure to 1) establish an 
accurate and timely explanation of the patient’s health problem(s) or 2) communicate that explanation to the 
patient.1 Thyroid cytology and histopathology are to some extent subjective areas of medical diagnosis and thus 
are subject to differing interpretations and potential likelihood of diagnostic error. The diagnostic pitfalls are 
relatively well documented.2,3 In histopathology, the pitfalls include papillary carcinoma (PTC) nuclei, a re-
quirement to use strict criteria for the diagnosis of capsular or vascular invasion in follicular thyroid carcinoma,4 
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benign nuclear bubbles (nuclear pseudo-pseudoinclu-
sions) resembling those seen in papillary thyroid carci-
noma,5 psammoma body-like dystrophic calcifications 
resembling calcifications seen in PTC,6 and benign par-
asitic nodules that can be mistaken for malignancy.7 In 
thyroid cytology, cystic lesions, acute suppurative thyroid-
itis, granulomatous thyroiditis, lymphocytic thyroiditis, 
Graves disease, noninvasive follicular thyroid neoplasm 
with papillary-like nuclei (NIFTP), oncocytic lesions, fol-
licular patterned lesions, papillary thyroid lesions, med-
ullary thyroid carcinoma, and oncocytic lesions can all 
create diagnostic problems.2 Diagnostic errors in thyroid 
cytology/histopathology may involve the preanalytical 
phase, which is the specimen collection and transmission 
process to the laboratory; the analytical phase, which is 
the diagnostic workup in the laboratory; or the postana-
lytical phase, which is the handling of the results outside 
the laboratory once the result is generated within the lab-
oratory. In the postanalytical phase, the communication 
of results is aided by close liaison with clinical teams and 
the use of standardized reporting terminology nomencla-
ture. Failsafe quality-management systems for tracking 
and follow-up of patients for a thyroid nodule clinic can 
be used to ensure quality of patient care and that results 
are acted upon.8 We have reviewed our experience in re-
lation to thyroid cytology/histopathology to provide a list 
of recommendations that could be used to potentially 
improve pathologic and clinical decision-making, ensure 
quality, and reduce diagnostic errors, especially for thy-
roid cytology. A list of 12 suggested recommendations is 
proposed from our personal experience and clinical prac-
tice in 3 different settings (Fig. 1). This suggested list of 
recommendations is developmental because, currently, it 
may not be possible to implement all of these in any given 
practice setting. This is not intended to be a comprehen-
sive or prescriptive framework but, rather, a proposal for 
a series of quality measures that could be implemented, 
according to their clinical practice, by cytopathologists, 
FIGURE 1. (Left) This flowchart illustrates preanalytical, analytical, and postanalytical aspects of the 12 suggested recommendations. 
(Right) The effect of multidisciplinary discussion enables review of 11 of the 12 suggested recommendations (excluding suggestion 
7; rapid on-site evaluation/aspirator training). FNAC indicates fine-needle aspiration cytology.
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histopathologists, and clinicians, who are the intended 
audience for this article.
1. Use a Standardized Reporting Terminology 
for Thyroid Fine-Needle Aspiration 
Cytology and All Thyroid Aspirates
The use of reporting terminologies for thyroid fine- 
needle aspiration (FNA) cytology (FNAC) dates back to 
the Papanicolaou Society Classification in 2005.9 After 
the Bethesda Thyroid Fine-Needle Aspiration State of the 
Science Conference in 2007 in Bethesda, Maryland, The 
Bethesda System for Reporting Thyroid Cytopathology 
(TBSRTC) was published in 2008, and the second edi-
tion was published in 2017.10 Other reporting termi-
nologies exist. There is the British Thy terminology,11 
the Italian TIR terminology,12 an Australian terminology, 
and a Japanese system.13 All of these systems are broadly 
similar, although with slight differences. All seek to clas-
sify and codify thyroid FNACs according to the likely 
histopathologic diagnosis, to give some indication of the 
risk of malignancy (ROM), and to suggest clinical man-
agement of the patient (Table 1). Reports should include 
both descriptive text, describing the cytologic findings of 
the lesions(s) and suggesting a diagnosis or differential di-
agnosis, and then a code for the final diagnostic terminol-
ogy category. For various reasons, some thyroid FNAs are 
still not always reported using a standardized terminol-
ogy, either through omission or because, on occasion, for 
valid reasons if it is not clear that an FNAC is necessarily 
arising from the thyroid gland or from a structure sur-
rounding the thyroid or lymph node. If a standardized 
FNAC terminology is not used, this can lead to ambigu-
ity and uncertainty in the understanding and application 
of the report to patient management.
2. Understand and Explain to Service 
Users the Limitations of Cytology and the 
Standardized Thyroid FNAC Reporting 
Terminology Used
Although using a standardized terminology is important, 
it is equally important to understand the intrinsic limita-
tions of thyroid FNAC in general and hence the reporting 
system used. Thyroid cytology requires both qualitative 
and quantitative interpretation of microscopic features. 
The interobserver reproducibility of the different sub-
categories of the various FNAC terminology systems is 
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personal and institutional case volume are factors, at best, 
studies demonstrate moderate, and sometimes very poor, 
interobserver reproducibility for some of the FNAC sub-
categories, particularly for Thy3a (κ = 0.11) (Fig. 2)18 
or atypia of undetermined significance/follicular lesion 
of undetermined significance (Bethesda category III). 
Cibas et al, using TBSRTC, demonstrated a 64% rate 
of concordance between local and central cytopathology 
review and 74.7% intraobserver concordance.20 Clinical 
decision making and follow-up depend on assigning a 
FIGURE 2. This diagram illustrates the interobserver reproducibility of the various categories within the UK Thy terminology system, 
indicating that interobserver reproducibility of the Thy 3a and Thy 4 categories is low. Thy 3a is equivalent to The Bethesda 
System for Reporting Thyroid Cytopathology category III (atypia of undetermined significance/follicular lesion of undetermined 
significance), and Thy 4 is equivalent to category V (suspicious of malignancy).
FIGURE 3. This is a heat-map of the responses of 47 participants to 12 static images of thyroid lesions showing wideinterobserver 
variation in the assessment of papillary carcinoma or benign nuclei. PTC indicates a participant diagnosis of papillary thyroid 
carcinoma based on assessment of the relevant static image. Only the first 6 cases are illustrated (Royal College of Pathologists 
Endocrine Pathology Update, 2018; see www.thyro id2018.com, accessed May 28, 2020). Reproduced with permission from NIFTP.org.
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particular FNAC to a particular category with a sug-
gested ROM. Because the interobserver reproducibility 
of the various reporting terminology subcategories in all 
terminology systems is not perfect, there is always some 
degree of uncertainty for the clinical management if this 
is based on the cytologic findings alone. For example, an 
FNA categorized as Thy 3a or Bethesda category III by 
an individual cytopathologist might be reasonably cat-
egorized as category II/Thy 2 (benign) or category IV/
Thy 3f (follicular neoplasm or suspicious for a follicu-
lar neoplasm) by another equally skilled and competent 
cytologist.18 Compounding the subjectivity of patho-
logic interpretation are the well known morphologic 
limitations of thyroid FNAC in the diagnosis of folli-
cular-patterned lesions, with the cytologic appearances 
of follicular adenoma and well differentiated follicular 
carcinoma often being identical. Histology diagnoses af-
fect the ROMs: according to TBSRTC, the positive pre-
dictive value for a malignant category VI thyroid FNAC 
is 97% to 99% if NIFTP lesions are included as malig-
nant and 94% to 96% if NIFTP lesions are no longer 
regarded as malignant.10 The degree of uncertainty in 
the subcategorization of thyroid FNAC can be expressed 
as confidence limits, at a significant level of 1 standard 
deviation or 2 standard deviations assuming a normal 
distribution of results around a mean value. However, in 
clinical practice, this is difficult to do given the subjec-
tivity of cytologic diagnosis and the known interobserver 
degree of variation. Therefore, it is important that cyto-
pathologists, histopathologists, and clinicians are aware 
of the limitations of thyroid cytology in general and the 
interobserver reproducibility of the various cytologic 
subcategories in the terminology system used and that 
they use this information in their clinical decision mak-
ing with full knowledge of the degree of uncertainty.
3. Review All Relevant Clinical and Ultrasound 
Findings (if Feasible and/or Available)
Many cytopathologists and histopathologists still receive 
specimens in the pathology laboratory with a laboratory 
request form that states, “thyroid nodule, ultrasound-
guided FNA.” It is important that thyroid FNACs are ap-
propriately labeled as to site(s) and side(s) (eg, left lobe, 
right lobe, or isthmus) to prevent inappropriate surgery. 
Thyroid FNAC slides can be viewed independent of the 
clinical history and ultrasound characteristics without 
the prior cognitive bias of the full details of the relevant 
clinical information, the medical history, and ultrasound 
findings; however, this ignores the wealth of clinical infor-
mation available, which is not typically included on pa-
thology laboratory request forms.21 This clinical history 
includes hematology and biochemistry results, which may 
be relevant to inflammatory or autoimmune conditions of 
the thyroid (eg, granulomatous or Hashimoto thyroiditis, 
elevated serum calcitonin and CEA levels, details of previ-
ous thyroid or head and neck surgery, or hypercalcemia 
in parathyroid lesions). The ultrasound characteristics of 
the nodule(s) and a grading or scoring system based on 
the ultrasound findings, as now recommended in major 
international guidelines, are also important.22,23 Hence a 
reduction in the potential for diagnostic error, if possible 
and if this information is available, requires knowledge of 
the clinical findings, clinical history, relevant laboratory 
investigations and ultrasound characteristics, or other im-
aging characteristics (eg, positron emission tomography/
computed tomography) of the nodule or thyroid lesions 
aspirated. It may also be possible for the cytopathologist 
to review the ultrasound images and include this informa-
tion in the cytopathologic assessment if the cytopatholo-
gist has training to do this.24
4. Include the Risk of Malignancy in All 
Cytopathology Reports (if Feasible)
The ROM is the probability that, if a thyroid nodule (or 
lesion) is excised, then the lesion will be malignant at histo-
pathologic examination. The TBSRTC second edition sug-
gests including the ROM in cytopathology reports,10 which 
is useful because it helps to convey to clinicians and patients 
the likely ROM and hence the cytologic level of concern. 
However, this may create anxiety in the patient, particularly 
because lesions that are cytologically concerning or malig-
nant may be clinically indolent or could be incidentally 
discovered nodules that are unlikely to progress: so-called 
thyroid incidentalomas.25 Nevertheless, knowledge of the 
ROM is crucial in guiding clinical management, including 
discussions with patients about the level of risk. The ROM 
provided ideally should be locally derived26; however, if this 
is not possible, then, as an alternative, the ROM quoted in 
the published literature for the relevant reporting terminol-
ogy could be included in the cytology report.10
It is important to consider carefully how the ROM is 
calculated. The TBSRTC ROM for each category is based 
Review Article
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on the published literature, whereas the local institutional 
ROM for each category may vary quite widely from the 
published literature.27 Patients with unsatisfactory or 
benign FNACs who undergo surgery are more likely to 
have clinicoradiologic features that are of concern than 
patients who do not. Hence using as a denominator the 
number of patients with subsequent histology is more rele-
vant for higher risk categories, in which most patients will 
undergo surgery. In contrast, a denominator comprising 
all patients in the relevant cytology terminology category 
will be more relevant for the benign and unsatisfactory 
categories, in which most patients will not undergo sur-
gery. As highlighted in recommendation 8, below, there 
is also considerable subjectivity in the benign or malig-
nant diagnosis of follicular-patterned lesions of the thy-
roid, hence histopathologic assessment cannot always be 
regarded as a true benchmark gold standard.4,20,28-30
5. Collect Data to Calculate the Local 
ROM and Ideally in Real-Time (if Feasible)
TBSRTC10 and the other international terminologies give 
a stated ROM for the various cytologic subcategories.11-13 
However, there is relatively wide interinstitutional vari-
ation in the ROM for the various categories, which is 
related to the subjectivity of thyroid cytology, the preva-
lence of thyroid cancer in the local population, and inter-
individual or interinstitutional factors, including patient 
management pathways.27,31-33 Hence. if feasible. accurate 
data can be obtained from local institutional cytologic/
histopathologic audit of the ROM for each of the cyto-
logic subcategories for the reporting terminology used. 
The process of information collection ideally should be 
contemporary, but it is recognized that there may be a 
delay before the patient has proceeded to surgery and con-
firmatory histologic assessment. The confidence intervals 
or the degree of certainty of the ROM within any given 
thyroid FNA terminology subcategory is difficult to calcu-
late; however, from a scientific perspective, the confidence 
limits of the ROM for each terminology subcategory are 
useful to know, hence we believe that, in the future, this 
will be something that service users will require.
6. Accept That Nondiagnostic FNAs Will 
Include Small Numbers of Carcinomas, 
Comprising Mainly Cystic PTC
The nondiagnostic category11-13,34 inevitably includes a 
small number of missed carcinomas, usually because the 
aspirator has failed to adequately sample the lesion or tar-
get the relevant lesion(s) seen on ultrasound or because the 
lesion is cystic. Retrospective studies have reported lower 
rates of both nondiagnostic and false-negative cytology 
from FNAC procedures performed using ultrasound guid-
ance compared with palpation.22 The nondiagnostic rate 
depends on the nature of the lesion aspirated and the expe-
rience of the aspirator. Unilocular thyroid cysts without ra-
diologically or ultrasound concerning features have a very 
low ROM, so, even if the aspirate contains only nonepithe-
lial material consistent with the cyst content, the ROM is 
low. Cysts with solid areas should be sampled in the solid 
component to avoid misdiagnosis of a cystic PTC. Solid 
lesions and some mixed cystic/solid lesions should produce 
a qualitative and quantitative cellular yield.
7. Rapid On-Site Evaluation and/or 
Educational Sessions for Aspirators Will 
Almost Certainly Reduce the Rate of 
Nondiagnostic Aspirates if the Number  
of Nondiagnostic Aspirates Is High
Rapid on-site evaluation (ROSE) is an important meas-
ure that can be implemented if the nondiagnostic rate is 
high.35 TBSRTC,10 the UK terminology system,11 and 
other terminologies suggest a minimum adequacy crite-
rion consisting of 6 groups of 10 epithelial cells for a spec-
imen to be considered adequate. Most published evidence 
shows that implementation of ROSE will reduce nondi-
agnostic rates for thyroid FNA if nondiagnostic rates are 
high.35 Who should undertake ROSE? This can be per-
formed by cytotechnologists and biomedical science staff 
or by pathologists and cytologists, depending on local 
institutional preference.36 It is also well documented that 
higher yields of satisfactory FNAC are seen with increas-
ing operator experience. Monitoring the rate of unsat-
isfactory specimens once aspirators are fully trained can 
identify underperformance, which can be addressed by 
additional specific training.
8. Know the Relevant Diagnostic Pitfalls  
of Both Cytopathology and Histopathology
There are multiple pitfalls in making diagnoses in thyroid 
cytology and pathology. These are dealt with elsewhere in 
several publications.2,3 In thyroid cytology, the principal 
diagnostic risks are underdiagnosis of a malignant condi-
tion, overdiagnosis as malignant or suspicious of malig-
nancy of a benign or very low ROM condition, or failure 
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to diagnose a benign inflammatory process as benign. In 
thyroid histopathology, many of the diagnostic pitfalls are 
very similar to those seen in cytology, particularly the di-
agnosis of papillary carcinoma-type nuclei and the mini-
mum histopathologic thresholds for a diagnosis of PTC 
or NIFTP.37-39
Regarding papillary carcinoma-like nuclei, there is 
significant interobserver variation in the histopathologic 
thresholds for diagnosis of the nuclei for PTC.29,30 This 
has been borne out by multiple articles in the literature. 
Another example of this is an exercise undertaken involv-
ing participants at a conference of the UK Endocrine 
Pathology Society and Royal College of Pathologists in 
2018. Forty-seven conference participants, all of whom 
were either established consultants or senior trainees in 
pathology, undertook an assessment of 12 photomicro-
graphic images from a sample of follicular-patterned thy-
roid tumors with the option to suggest a diagnosis of PTC 
or benign nuclei (the images of the 12 thyroid lesions can 
be viewed at www.thyro id2018.com, accessed May 28, 
2020). The heat map of responses shown in Figure 3 in-
dicates that, in difficult cases, there can be wide interob-
server variation in the diagnosis of PTC or benign. With 
the use of NIFTP terminology, reference to the older lit-
erature from before 2016 becomes problematic because, 
in many series, approximately 20% to 25% of newly di-
agnosed thyroid carcinomas before 2016 were diagnosed 
as encapsulated follicular variant of PTC, many of which 
would now be diagnosed as NIFTP lesions.37 The litera-
ture shows that up to 8% of FNAs classified as malignant 
and approximately 24% of those classified as suspicious 
of malignancy are NIFTP lesions.40,41 When a NIFTP 
tumor is suspected, free text comments are suggested (eg, 
overall cytomorphologic features suggest a follicular vari-
ant of papillary carcinoma or its recently described indo-
lent counterpart, NIFTP; definitive distinction between 
these is not possible on cytologic material10). The latest 
edition of TBSRTC has revised the cytologic criteria for 
diagnosis of PTC.10 Lesions with follicular architecture 
that lack intranuclear cytoplasmic inclusions are now 
regarded as suspicious of malignancy rather than malig-
nant. Conversely, the presence on FNAC of either ≥3 nu-
clear pseudoinclusions or true papillae and/or psammoma 
bodies is highly predictive of a diagnosis of PTC.42
There is very poor interobserver reproducibility, 
as evidenced by κ statistics for the diagnosis of capsu-
lar invasion and vascular invasion in follicular thyroid 
carcinoma,28 further compounding difficulty in the his-
topathologic diagnosis of follicular-patterned lesions for 
benign versus malignant. Published evidence shows rates 
of interrater disagreement for histopathologic assessment 
of thyroid nodules for a benign diagnosis versus a ma-
lignant diagnosis of 9.7%, with concordance between 2 
expert histopathologists in 691 of 765 nodules.20 The 
level of agreement increased to 98.5% after the 2 experts 
conferred.
9. Use Special Immunohistochemical and 
Molecular Techniques That Are Evidence-
Based Immunohistochemistry
Cytohistologic cell-block examination with immuno-
histochemistry is useful in thyroid FNAC.43 Examples 
include confirmation of the diagnosis of medullary 
thyroid carcinoma, which is typically positive for calci-
tonin and mCEA; anaplastic thyroid carcinoma, which 
is typically negative for thyroglobulin and TTF1 and 
positive for PAX-8; parathyroid lesions which are usu-
ally negative for thyroglobulin and TTF1 and positive 
for parathormone, chromogranin A, and GATA 3. It is 
also useful for suspected metastatic tumors to the thyroid 
(eg, a carcinoma of unknown primary site panel or an-
other tailored immunopanel for the suspected primary 
site). Immunohistochemical panels for the distinction of 
benign and malignant follicular lesions are not recom-
mended because of problems standardizing the results 
obtained in differing laboratories.43
MOLECULAR TECHNIQUES
The use of molecular techniques for thyroid lesions is 
now common, particularly in North America, where vari-
ous proprietary systems are marketed. The most specific 
single molecular diagnostic test is BRAF V600E muta-
tion, which, if present, indicates with 99% certainty the 
presence of thyroid carcinoma.44 However, as a screening 
test, the sensitivity of BRAF V600E mutation is too low 
to reliably rule out thyroid carcinoma.45 Other gene mu-
tations may be useful and suggest adverse prognosis (eg, 
TERT promoter mutation, PIK3CA, TP53, and AKT1). 
Gene mutations such as RAS have much less clinical value 
because these mutations are present at low frequency in 
both benign and malignant lesions.46-48 Molecular tests 
for thyroid cytology can be used as rule-in or rule-out tests 
for thyroid carcinoma. Afirma, ThyGeNEXT/ThyraMIR 
(Interpace Diagnostics), or ThyroSeq 3 (University of 
Review Article
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Pittsburgh Medical Center/CBLPath) are the 3 principal 
test methodologies available and are most useful for inde-
terminate thyroid nodules.49 The limitations of molecular 
diagnosis are that its positive and negative predictive val-
ues are very much influenced by the prevalence of cancer 
in the relevant cytologic category, which may vary widely 
between institutions.50 Comparison of validation stud-
ies in TBSRTC category III for ThyroSeq v3, ThyGenX/
ThyraMIR, and Afirma show respective sensitivities of 
94%, 89%, and 91%; specificities of 82%,85%, and 
68%; negative predictive values for malignancy of 97%, 
94%, and 96%; and positive predictive values for malig-
nancy of 66%, 74%, and 47%.49 Therefore, molecular 
testing has some limitations in clinical practice, and pa-
tients and clinicians need to be aware of them. Molecular 
clinical practice continues to evolve in response to new 
developments. For NIFTP genotyping, panels frequently 
show NRAS/HRAS mutations and THADA fusions and 
Afirma gene expression classifier suspicious results.49 The 
Afirma test has a high negative predictive value for ma-
lignancy but a lower positive predictive value for malig-
nancy, hence approximately one-half of patients with 
Afirma gene expression classifer suspicious calls do not 
have thyroid cancer.51
10. Second Opinions Are Very Valuable and 
May Be In-House or Interinstitutional
In-house second opinions are useful for reducing inter-
pretation errors, which some centers achieve through 
in-house internal consensus conferences, with external 
second opinions being sought for the most challenging 
cases.52-54 In-house second opinions in thyroid pathology, 
although useful and relatively easy to obtain, may be sub-
ject to so-called leadership bias28 in contrast to externally 
obtained second opinions. The Association of Directors 
of Anatomic and Surgical Pathology many years ago rec-
ommended that, if a patient is transferred or referred to 
another institution, the pertinent pathology slides and 
reports should be reviewed at the second institution,55 
hence second-opinion pathology review is valuable.56 
There are multiple studies examining the usefulness of 
second opinions in thyroid FNAC. In a review by Gerhard 
and Boerner in 2014, of a total of 7154 thyroid FNAs 
reviewed, there was an overall discrepancy rate between 
the initial diagnosis and the second-opinion diagnosis of 
28.6%.57 In general, the second-opinion diagnosis was 
better supported by clinical follow-up than the histologic 
diagnosis. Almost one-third (30.4%) of discordant cases 
resulted in changes in the clinical management of patients 
with thyroid nodules. Those authors found that thy-
roid FNACs initially categorized as indeterminate could 
often be definitively classified as benign or malignant by 
a second-opinion diagnosis. This illustrates the value of 
seeking another pathologist’s opinion on a case. If there is 
interobserver diagnostic discrepancy, then an overall con-
sensus opinion or a third opinion can be sought.
11. Multidisciplinary Discussion of Cases 
Before Surgery or Therapy Is Invaluable
Most published reporting terminologies for cytopathol-
ogy do not require multidisciplinary discussion as a 
mandatory core element, with the exception of the UK 
Thy terminology.11 The advantage of multidisciplinary 
discussion is that it allows the diagnostic and therapeutic 
decisions to be revisited before the final decision for any 
individual patient is made by a team of multidisciplinary 
experts. Reviewing the current list of 12 recommenda-
tions, 11 of the 12 proposed recommendations could be 
addressed in the thyroid multidisciplinary meeting, (Fig. 
1, right). The 2015 US National Institute of Medicine 
report on improving diagnosis in health care states that 
treatment planning conferences (also known as tumor 
boards) may help to identify and avoid potential diagnos-
tic errors by bringing multiple perspectives to challenging 
diagnoses and comments that this approach could also be 
applied to diagnoses other than cancer, especially those 
with serious health consequences or complex symptom 
presentations.1 Good clinical practice suggests that, in 
an ideal situation, all FNACs could be reviewed jointly 
with the cytopathologist, radiologist, and endocrinolo-
gist or surgeon. As a measure of good clinical practice, 
all patients for whom therapy or surgery is being con-
sidered or is required may be reviewed in the multidis-
ciplinary setting with the radiologist, cytopathologist/
histopathologist, surgeon, endocrinologist, nuclear medi-
cine physician, and oncologist. However, this is difficult 
to achieve, and multidisciplinary working arrangements 
may vary, depending on the local practice setting. In the 
United Kingdom, The Royal College of Pathologists rec-
ommends that thyroid cytology cases categorized as Thy4 
or Thy5 (equivalent to TBSRTC categories V and VI, re-
spectively) will be reviewed by a cytologist/histopatholo-
gist member of the thyroid multidisciplinary team and 
discussed in the multidisciplinary setting.11 Other cases, 
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such as Thy3a and Thy3f (equivalent to TBSRTC cat-
egories III and IV, respectively) and cases classed as Thy1 
or Thy2 (equivalent to TBSRTC categories I and II, re-
spectively), can benefit from multidisciplinary discussion, 
especially if there is any concern.11
In some parts of the world, multidisciplinary teams 
are well established, although local practice may vary.58 The 
quality of cytopathologic assessment and reporting can be 
improved by local cytopathologists working with regional 
and national cytopathology experts.59 The issues discussed 
above in relation to cytopathologic/histopathologic diagno-
sis suggest that multidisciplinary discussion will most likely 
be of value for most patients. The ultrasound characteristics 
of a given thyroid lesion or nodule(s), the cytopathologic 
interpretation of the nodule(s), including in-house or in-
terinstitutional second opinions, and the histopathologic 
assessment of needle-core biopsy or of the excised thyroid 
specimen(s) are all potentially subjective, at least to some 
limited extent, with ultrasound imaging and cytology hav-
ing the highest rates of interobserver variation. This sug-
gests that at, every stage of the diagnostic process, there is 
potential for some diagnostic uncertainty; therefore, deci-
sion making in thyroid disease is not binary (yes or no) 
but requires the combined input of multiple specialties and 
expertise into decision making for patient management.
12. Manage Patient and Clinician 
Expectations of Thyroid Cytopathology  
and Histopathology
This is a difficult area for pathology and cytopathology 
but is essential in multidisciplinary patient management. 
Managing patient and clinician expectations requires 
multidisciplinary input, both when providing the cytol-
ogy or histopathology reports and when explaining the 
limitations of cytologic and histopathologic assessment. 
The clinical history and presentation and the radiologic, 
cytologic, and pathologic findings must be reviewed care-
fully and considered together. Patient preference and the 
extent of surgery undertaken require shared multidiscipli-
nary clinical decision making with patients. Although we 
would not necessarily advocate this for thyroid cytology, 
various initiatives have been proposed, including pathology 
explanation clinics for laboratory results, to try and help 
patients understand the meaning and relevance of their 
pathology results.60 For examplean important issue would 
be to explain to patients before surgery that most of those 
with cytologically indeterminate thyroid nodules diagnosed 
as follicular neoplasm/suspicious of follicular neoplasm after 
undergoing surgery are unlikely to have carcinoma.
Conclusions
The objective of this brief review is to provide patholo-
gists and clinicians with useful suggestions to reduce diag-
nostic errors, assist in quality-improvement initiatives for 
thyroid FNAC, and encourage and stimulate debate and 
discussion of error and decision making in thyroid cy-
tology and histopathology. This list of recommendations 
is developmental but represents a framework that should 
be helpful to reduce diagnostic error and improve clinical 
decision making after thyroid FNA.
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Measures to Reduce Diagnostic Error and Improve Clinical Decision Making in Thyroid FNA Aspiration 
Cytology: A Proposed Framework
David N. Poller, Sarah J. Johnson, and Massimo Bongiovanni
This review discusses the reasons for diagnostic error in thyroid cytology and histopathology and provides 12 recommendations 
for cytology and histopathology to improve quality and reduce the likelihood of clinical diagnostic errors. For each of the 12 
recommendations, the rationale is explained together with the overarching requirement for multidisciplinary case discussion 
if there is clinical or diagnostic uncertainty.
